Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
601-620 of 1,782 trials

CRSwNP: Predicting Response to Mepolizumab

We are studying biomarkers to see if they can help predict how well patients with CRSwNP respond to the treatment mepolizumab. This research aims to improve personalized treatment options for these patients.

Chronic Rhinosinusitis with Nasal Polyps≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyOtolaryngology

Advanced Colon Cancer: Preoperative Chemotherapy Study

We are investigating whether chemotherapy before surgery is more effective than surgery followed by additional treatment for advanced colon cancer. This trial aims to improve treatment strategies for patients.

Colon Cancer (Stage T3-4)>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Polymyalgia Rheumatica: Secukinumab Safety Study

We are evaluating the long-term safety of secukinumab for individuals with polymyalgia rheumatica. This study will help us understand any potential side effects associated with this treatment.

Polymyalgia Rheumatica>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Postmenopausal Bone Health: Everolimus and Exercise Study

We are investigating whether everolimus, exercise, or both can improve bone formation in healthy postmenopausal women. This study aims to help prevent bone loss and support skeletal health.

Healthy Participants3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyInternal MedicineOrthopedics and Traumatology

Breast Cancer Treatment for Women 70+: Radiation vs. Hormone Therapy

We are comparing radiation therapy and hormone therapy for older women with early-stage luminal A-like breast cancer. The goal is to see which treatment better controls cancer and improves quality of life.

Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Childhood Absence Epilepsy: Brivaracetam Safety Study

We are studying the long-term safety of brivaracetam in children and young adults with childhood or juvenile absence epilepsy. This research aims to understand how well the medication is tolerated over time.

Childhood Absence EpilepsyJuvenile Absence Epilepsy>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics

Lymphoblastic Lymphoma: New Treatment Protocol for Kids

We are studying whether changing medications during treatment can help reduce relapses in the brain for children and adolescents with lymphoblastic lymphoma. This trial aims to improve survival rates and treatment outcomes compared to standard approaches.

Lymphoblastic Lymphoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

ROS1-Positive Lung Cancer: REPotrectinib Study

We are testing a new treatment for patients with ROS1-positive non-small cell lung cancer and active brain metastasis. The study aims to see how well it works in shrinking brain tumors and to assess its safety.

ROS1-positive Non-Small Cell Lung Cancer with Brain Metastasis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurologyOncology

Chronic Myeloid Leukemia: Asciminib for Kids

We are studying the safety and appropriate dose of asciminib in children with chronic myeloid leukemia. This research aims to ensure the medication is safe and effective for young patients who have already tried other treatments.

Philadelphia Positive Chronic Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPediatrics

Methylprednisolone for Infants with Neuroendocrine Cells Hyperplasia

We are studying whether methylprednisolone pulses can reduce the need for oxygen therapy in infants with NEHI. The trial also examines the treatment's effects on respiratory health and quality of life.

Neuroendocrine Cell Hyperplasia of Infancy>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicinePulmonology

Intrathecal Baclofen for Spinal Cord Injury: Safety Study

We are investigating whether intrathecal baclofen is safe for spinal cord injury patients, particularly regarding lung function and sleep disorders. The study also looks at its potential to reduce muscle stiffness and improve daily activities.

Spinal Cord Injury>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyPulmonology

Thrombosis Prevention in Surgery: Apixaban Study

We are studying whether the medication apixaban can help prevent blood clots in patients undergoing general abdominal, gynecologic, and urologic surgeries. This trial compares its effects to not using any anticoagulants during surgery.

Venous Thromboembolism>2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteGynecology and ObstetricsInternal MedicineOrthopedics and TraumatologyUrology

Heart Procedure: Short vs. Long Antiplatelet Therapy

We are studying whether a shorter duration of antiplatelet therapy after a heart procedure is as safe and effective as the standard longer treatment. This trial is for patients who have had coronary angioplasty for blocked arteries.

Chronically Occluded Coronary Artery>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Dexamethasone for Severe Hospital-Acquired Pneumonia

We are studying whether dexamethasone can improve outcomes for critically ill patients with severe hospital-acquired pneumonia. This trial will also assess safety and how patients feel about the treatment.

Hospital-acquired Pneumonia>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Crohn's Disease: Vedolizumab vs. Adalimumab Dose Increase

We are studying whether Vedolizumab is more effective than increasing the dose of Adalimumab for Crohn's disease patients who are not responding well to their current treatment. This trial will help us understand which strategy leads to better remission and fewer side effects.

Crohn's Disease3-6 monthsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Meningococcal Vaccine Study for Infants and Toddlers

We are investigating a new meningococcal vaccine to see how well it works and its safety compared to an existing vaccine in healthy infants and toddlers. This study focuses on children receiving their first doses at 6-7 months and a booster at 12-13 months.

Meningococcal Infection6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesPediatrics

Kidney Transplant Rejection: Efgartigimod PH20 SC

We are studying a new treatment for kidney transplant recipients facing antibody-mediated rejection. The trial aims to evaluate the safety and how well this medication works compared to a placebo.

Antibody-Mediated Rejection1-2 yearsEfficacy phase (II)16-20 visitsStandard MedicinesCost ReimbursementInternal MedicineNephrology

Roxadustat: Impact on Heart and Metabolism

We are investigating how roxadustat influences glucose and fat metabolism and heart function in participants. This study may help us understand its potential benefits for cardiovascular health.

Risk Factors for Cardiovascular DiseaseMetabolic Syndrome1-2 yearsMonitoring phase (IV)Standard MedicinesCardiologyEndocrinologyInternal Medicine

Hepatocellular Carcinoma: Atezolizumab-Bevacizumab with Bacterial Supplements

We are studying whether adding bacterial supplements to a combination of atezolizumab and bevacizumab helps patients with hepatocellular carcinoma who have not responded to first-line treatment. The trial also looks at the safety of this new approach.

Non-resectable Hepatocellular Carcinoma1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyOncology

Antiplatelet Therapy Duration After TAVI

We are studying whether a shorter 3-month antiplatelet therapy is as effective as the standard 12-month therapy after TAVI. The goal is to see if it reduces complications and bleeding risks.

Aortic Stenosis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine